270 related articles for article (PubMed ID: 36130766)
1. Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort.
Berthe P; Scailteux LM; Lescoat A; Staumont D; Coiffier G; Guéret P; Dupuy A; Oger E; Droitcourt C
BMJ Open; 2022 Sep; 12(9):e059979. PubMed ID: 36130766
[TBL] [Abstract][Full Text] [Related]
2. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
[TBL] [Abstract][Full Text] [Related]
3. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
Atzeni F; Popa CD; Nucera V; Nurmohamed MT
Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
[TBL] [Abstract][Full Text] [Related]
4. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study.
Song YJ; Cho SK; Kim JY; You SH; Kim H; Jung SY; Sung YK
Semin Arthritis Rheum; 2023 Aug; 61():152214. PubMed ID: 37172496
[TBL] [Abstract][Full Text] [Related]
5. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis.
Ertus C; Scailteux LM; Lescoat A; Berthe P; Auffret V; Dupuy A; Oger E; Droitcourt C
Br J Dermatol; 2023 Sep; 189(4):368-380. PubMed ID: 37410552
[TBL] [Abstract][Full Text] [Related]
6. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
Hoisnard L; Pina Vegas L; Dray-Spira R; Weill A; Zureik M; Sbidian E
Ann Rheum Dis; 2023 Feb; 82(2):182-188. PubMed ID: 36198438
[TBL] [Abstract][Full Text] [Related]
7. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety.
Elmariah SB; Smith JS; Merola JF
Am J Clin Dermatol; 2022 Jul; 23(4):427-431. PubMed ID: 35679017
[TBL] [Abstract][Full Text] [Related]
8. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.
Chen TL; Lee LL; Huang HK; Chen LY; Loh CH; Chi CC
JAMA Dermatol; 2022 Nov; 158(11):1254-1261. PubMed ID: 36001310
[TBL] [Abstract][Full Text] [Related]
9. JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register.
Faquetti ML; Vallejo-Yagüe E; Cordtz R; Dreyer L; Burden AM
PLoS One; 2023; 18(7):e0288757. PubMed ID: 37498856
[TBL] [Abstract][Full Text] [Related]
10. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
11. Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population.
Montez-Rath ME; Lubwama R; Kapphahn K; Ling AY; LoCasale R; Robinson L; Chandross KJ; Desai M
Curr Med Res Opin; 2022 Aug; 38(8):1431-1437. PubMed ID: 35699028
[TBL] [Abstract][Full Text] [Related]
12. A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis.
Wollenberg A; Thyssen JP; Bieber T; Chan G; Kerkmann U
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2041-2046. PubMed ID: 37319107
[TBL] [Abstract][Full Text] [Related]
13. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies.
Daniele S; Bunick C
J Drugs Dermatol; 2022 Dec; 21(12):1298-1303. PubMed ID: 36468956
[TBL] [Abstract][Full Text] [Related]
14. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
Alten R; Mischkewitz M; Stefanski AL; Dörner T
Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
[TBL] [Abstract][Full Text] [Related]
15. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
Reddy V; Cohen S
Curr Opin Rheumatol; 2021 May; 33(3):300-306. PubMed ID: 33767091
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
17. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
18. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
Xie W; Huang Y; Xiao S; Sun X; Fan Y; Zhang Z
Ann Rheum Dis; 2019 Aug; 78(8):1048-1054. PubMed ID: 31088790
[TBL] [Abstract][Full Text] [Related]
19. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.
Ingrassia JP; Maqsood MH; Gelfand JM; Weber BN; Bangalore S; Lo Sicco KI; Garshick MS
JAMA Dermatol; 2024 Jan; 160(1):28-36. PubMed ID: 37910098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
